Emfo LLC Lowers Position in Pfizer Inc. (NYSE:PFE)

Emfo LLC lessened its position in Pfizer Inc. (NYSE:PFE) by 54.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,221 shares of the biopharmaceutical company’s stock after selling 3,860 shares during the quarter. Emfo LLC’s holdings in Pfizer were worth $93,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. raised its stake in Pfizer by 40.5% during the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock valued at $157,215,000 after buying an additional 1,365,295 shares during the last quarter. Brookstone Capital Management increased its holdings in shares of Pfizer by 88.5% in the 3rd quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock worth $14,109,000 after purchasing an additional 212,369 shares in the last quarter. ETF Store Inc. increased its holdings in shares of Pfizer by 12.0% in the 3rd quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock worth $214,000 after purchasing an additional 727 shares in the last quarter. Farmers Trust Co. increased its holdings in shares of Pfizer by 2.0% in the 4th quarter. Farmers Trust Co. now owns 225,881 shares of the biopharmaceutical company’s stock worth $6,503,000 after purchasing an additional 4,410 shares in the last quarter. Finally, Wealthspire Advisors LLC increased its holdings in shares of Pfizer by 21.4% in the 3rd quarter. Wealthspire Advisors LLC now owns 150,164 shares of the biopharmaceutical company’s stock worth $4,981,000 after purchasing an additional 26,455 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.2 %

NYSE:PFE traded up $0.04 during midday trading on Monday, hitting $25.90. The stock had a trading volume of 35,623,531 shares, compared to its average volume of 42,737,133. Pfizer Inc. has a one year low of $25.61 and a one year high of $41.33. The company has a market capitalization of $146.66 billion, a price-to-earnings ratio of 72.39, a PEG ratio of 1.16 and a beta of 0.61. The stock has a 50-day moving average of $27.28 and a 200 day moving average of $28.88. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The company had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. Pfizer’s revenue was down 41.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.14 earnings per share. As a group, sell-side analysts forecast that Pfizer Inc. will post 2.22 EPS for the current year.

Analyst Ratings Changes

Several analysts recently commented on PFE shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a report on Thursday, January 4th. Guggenheim started coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. Finally, Argus lowered Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Twelve investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $36.88.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.